Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Diabetes Health Mobile App
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (0)

Study Says Type 2s Don't Benefit as Much From Good Cholesterol


Jan 9, 2010

Cholesterol is mostly insoluble in water and travels in the blood stream in the form of lipoproteins. It is carried from the intestinal mucosa to the liver in chylomicrons. In the liver it is converted into low-density lipoprotein (LDL) and takes cholesterol to the body cells, while high-density lipoprotein (HDL) carries it to the liver for excretion. Note that the cholesterol in LDL cholesterol and the cholesterol in HDL cholesterol are identical. The only difference between the two is the carrier molecule (the lipoprote).

German and Swiss researchers have found that high-density lipoprotein, or HDL-so-called "good" cholesterol-does not protect blood vessels in people with type 2 diabetes as well as it does in people who don't have the disease. However, their follow-up experiment, which added doses of extended-release niacin, shows that HDL's efficacy in type 2s might be sharply increased simply by the addition of a daily niacin pill.

HDL, which carries "bad" cholesterol-low-density lipoprotein-away from arteries, is thought to reduce cardiovascular disease by thwarting the build-up of plaque and removing chemicals that damage arterial walls and reduce their flexibility. Medical scientists consider high levels of HDL to be one indicator of a lower risk of heart disease.

Researchers at the University Hospital Zurich in Switzerland and the Medical School of Hanover in Germany studied 10 non-diabetic patients and 33 people with type 2 diabetes or metabolic syndrome to see how HDL affected the health of their blood vessels. (The diabetes patients were already taking cholesterol-lowering medication and had low levels of HDL as well.) The scientists found that the ability of HDL to protect blood vessels in type 2s was "substantially impaired."

To see if they could increase HDL levels and functionality in the people with diabetes, the researchers split the type 2s into two groups, one taking a placebo and the other taking 1,500 mg daily of extended-release niacin. Previous studies had shown that niacin increases HDL and lowers other fats in the blood.

After three months, the type 2s taking the niacin had increased HDL levels and improved vascular function. The placebo group showed no similar increases or improvements.

Given that the study group was extremely small, the Swiss and German researchers will not recommend extended-release niacin as a routine treatment for some type 2s until a much larger, more formal study can confirm their findings.

* * *

Source:

http://www.physorg.com/news180639450.html


Categories: Complications & Care, Diabetes, Medications, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jan 9, 2010

©1991-2012 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.